| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The active metabolite 6-MP is a purine antimetabolite that inhibits amidophosphoribosyltransferase and incorporates into DNA/RNA, disrupting nucleic acid synthesis and inducing apoptosis; azathioprine also causes intracellular glutathione depletion in hepatocytes at relevant concentrations, contributing to its immunosuppressive and toxic effects.
|
|---|---|
| ln Vitro |
In primary rat and human hepatocytes, azathioprine (0-50 μM, 48 hours) sodium causes substantial intracellular GSH depletion at relevant doses [2].
In primary rat and human hepatocytes, azathioprine sodium (0–50 μM, 48 h) causes substantial intracellular glutathione (GSH) depletion at relevant doses; it induces apoptosis and inhibits lymphocyte proliferation through 6-MP–mediated purine antagonism, with myelosuppressive effects observed in vitro. |
| ln Vivo |
Azathioprine (oral gavage, 25-400 mg/kg, daily, 10 days) sodium can alter associated parameters such as bone marrow cells, red blood cells, and peripheral blood cytokines in a dose-dependent manner, and can induce apoptosis of female CD-cells. 1 mice and ICR mice [3].
In vivo, azathioprine sodium (oral gavage, 25–400 mg/kg daily for 10 days) dose-dependently alters bone marrow cells, erythrocytes, and peripheral blood cytokines, and induces apoptosis in female CD-1 cells; it is an immunosuppressive agent used in autoimmune disease and transplant models. |
| Enzyme Assay |
Azathioprine is a prodrug and is not typically assayed directly for enzyme inhibition; its conversion to 6-MP is measured by HPLC in plasma or tissue homogenates, and 6-MP metabolites (6-thioguanine nucleotides, 6-methylmercaptopurine) are quantified in erythrocytes by HPLC or LC-MS/MS; GSH depletion is measured by a recycling assay with glutathione reductase and DTNB.
|
| Cell Assay |
Cell viability assay [2]
Cell Types: rat hepatocytes, human hepatocytes Tested Concentrations: 0-50 μM Incubation Duration: 24-48 hrs (hours) Experimental Results: It shows that the cell viability and intracellular GSH level of rat hepatocytes diminished at a low concentration of 0.5 μM , but not diminished. In human hepatocytes, cell viability was Dramatically diminished at concentrations below 50 μM, and GSH depletion was clearly noted at concentrations as low as 1 μM. Primary rat or human hepatocytes are treated with azathioprine sodium (0–50 μM) for 48 h; intracellular GSH is measured by a recycling assay, apoptosis by caspase-3 activity or annexin V staining, and cell viability by tetrazolium or luminescence assays; lymphocyte proliferation is measured by thymidine incorporation or CFSE dilution in PBMC cultures. |
| Animal Protocol |
Animal/Disease Models: outbred female CD-1 mice, female ICR mice [3]
Doses: 25-400 mg/kg Route of Administration: po (oral gavage); every day; 10 days Experimental Results: Result in red blood cell related parameters and white blood cell related parameters. diminished in a dose-dependent manner. fms-like tyrosine kinase 3 (FLT-3) induced bone marrow cell reduction by 52.4%, 35.4%, 17.9%, 16.1% and 15.2% ligand at concentrations of 40, 60, 80, 100 and 120 mg/kg, respectively ( FL) related cytokines increased. Increased induction of apoptosis. Mice or rats receive azathioprine sodium by oral gavage at 25–400 mg/kg daily for 10 days; bone marrow cellularity, erythrocyte counts, and peripheral blood cytokines are measured, apoptosis in bone marrow cells is assessed by TUNEL or caspase-3 staining, and 6-MP metabolite levels in erythrocytes are quantified to correlate exposure with immunosuppressive and toxic effects. |
| References |
[1]. SoniaChavez-Alvarez, et al. Azathioprine: its uses in dermatology. An Bras Dermatol. 2020 Nov-Dec;95(6):731-736.
[2]. Yue-Ting Wu, et al. Azathioprine hepatotoxicity and the protective effect of liquorice and glycyrrhizic acid. Phytother Res. 2006 Aug;20(8):640-5. doi: 10.1002/ptr.1920. [3]. Gemma Molyneux, et al. The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse. Int J Exp Pathol. 2008 Apr;89(2):138-58. |
| Additional Infomation |
Azathioprine sodium is the sodium salt form of azathioprine, a prodrug of a purine analogue with immunosuppressive activity. In vivo, azathioprine is converted to its active metabolite, 6-mercaptopurine (6-MP), which replaces the normal nucleoside and is incorrectly incorporated into the DNA sequence. This leads to inhibition of DNA, RNA, and protein synthesis. Consequently, cell proliferation may be suppressed, particularly in lymphocytes and leukocytes. Azathioprine sodium is an immunosuppressant often used in combination with cyclophosphamide and hydroxychloroquine to treat rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th Edition) See also: Azathioprine (broadly defined).
|
| Molecular Formula |
C9H7N7O2S.NA+
|
|---|---|
| Molecular Weight |
300.25
|
| Exact Mass |
299.02
|
| CAS # |
55774-33-9
|
| Related CAS # |
Azathioprine;446-86-6
|
| PubChem CID |
11529527
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
129
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
354
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C=NC(=C1SC2=NC=NC3=C2N=C[N-]3)[N+](=O)[O-].[Na+]
|
| InChi Key |
WISNYKIQFMKSDQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H6N7O2S.Na/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8;/h2-4H,1H3;/q-1;+1
|
| Chemical Name |
sodium;6-(3-methyl-5-nitroimidazol-4-yl)sulfanylpurin-9-ide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3306 mL | 16.6528 mL | 33.3056 mL | |
| 5 mM | 0.6661 mL | 3.3306 mL | 6.6611 mL | |
| 10 mM | 0.3331 mL | 1.6653 mL | 3.3306 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.